The Glycobiology of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease of complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low survival rate. Multiple reports have shown that idiopathic PAH, or IPAH, is associated with metabolic dysregulation including alt...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/4/316 |
| _version_ | 1797410068770062336 |
|---|---|
| author | Shia Vang Phillip Cochran Julio Sebastian Domingo Stefanie Krick Jarrod Wesley Barnes |
| author_facet | Shia Vang Phillip Cochran Julio Sebastian Domingo Stefanie Krick Jarrod Wesley Barnes |
| author_sort | Shia Vang |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease of complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low survival rate. Multiple reports have shown that idiopathic PAH, or IPAH, is associated with metabolic dysregulation including altered bioavailability of nitric oxide (NO) and dysregulated glucose metabolism. Multiple processes such as increased proliferation of pulmonary vascular cells, angiogenesis, apoptotic resistance, and vasoconstriction may be regulated by the metabolic changes demonstrated in PAH. Recent reports have underscored similarities between metabolic abnormalities in cancer and IPAH. In particular, increased glucose uptake and altered glucose utilization have been documented and have been linked to the aforementioned processes. We were the first to report a link between altered glucose metabolism and changes in glycosylation. Subsequent reports have highlighted similar findings, including a potential role for altered metabolism and aberrant glycosylation in IPAH pathogenesis. This review will detail research findings that demonstrate metabolic dysregulation in PAH with an emphasis on glycobiology. Furthermore, this report will illustrate the similarities in the pathobiology of PAH and cancer and highlight the novel findings that researchers have explored in the field. |
| first_indexed | 2024-03-09T04:23:32Z |
| format | Article |
| id | doaj.art-0bdbc6f25d4145be99f2a85a8950aaba |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T04:23:32Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-0bdbc6f25d4145be99f2a85a8950aaba2023-12-03T13:42:55ZengMDPI AGMetabolites2218-19892022-04-0112431610.3390/metabo12040316The Glycobiology of Pulmonary Arterial HypertensionShia Vang0Phillip Cochran1Julio Sebastian Domingo2Stefanie Krick3Jarrod Wesley Barnes4Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USAPulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease of complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low survival rate. Multiple reports have shown that idiopathic PAH, or IPAH, is associated with metabolic dysregulation including altered bioavailability of nitric oxide (NO) and dysregulated glucose metabolism. Multiple processes such as increased proliferation of pulmonary vascular cells, angiogenesis, apoptotic resistance, and vasoconstriction may be regulated by the metabolic changes demonstrated in PAH. Recent reports have underscored similarities between metabolic abnormalities in cancer and IPAH. In particular, increased glucose uptake and altered glucose utilization have been documented and have been linked to the aforementioned processes. We were the first to report a link between altered glucose metabolism and changes in glycosylation. Subsequent reports have highlighted similar findings, including a potential role for altered metabolism and aberrant glycosylation in IPAH pathogenesis. This review will detail research findings that demonstrate metabolic dysregulation in PAH with an emphasis on glycobiology. Furthermore, this report will illustrate the similarities in the pathobiology of PAH and cancer and highlight the novel findings that researchers have explored in the field.https://www.mdpi.com/2218-1989/12/4/316pulmonary hypertensionglycobiologymetabolism |
| spellingShingle | Shia Vang Phillip Cochran Julio Sebastian Domingo Stefanie Krick Jarrod Wesley Barnes The Glycobiology of Pulmonary Arterial Hypertension Metabolites pulmonary hypertension glycobiology metabolism |
| title | The Glycobiology of Pulmonary Arterial Hypertension |
| title_full | The Glycobiology of Pulmonary Arterial Hypertension |
| title_fullStr | The Glycobiology of Pulmonary Arterial Hypertension |
| title_full_unstemmed | The Glycobiology of Pulmonary Arterial Hypertension |
| title_short | The Glycobiology of Pulmonary Arterial Hypertension |
| title_sort | glycobiology of pulmonary arterial hypertension |
| topic | pulmonary hypertension glycobiology metabolism |
| url | https://www.mdpi.com/2218-1989/12/4/316 |
| work_keys_str_mv | AT shiavang theglycobiologyofpulmonaryarterialhypertension AT phillipcochran theglycobiologyofpulmonaryarterialhypertension AT juliosebastiandomingo theglycobiologyofpulmonaryarterialhypertension AT stefaniekrick theglycobiologyofpulmonaryarterialhypertension AT jarrodwesleybarnes theglycobiologyofpulmonaryarterialhypertension AT shiavang glycobiologyofpulmonaryarterialhypertension AT phillipcochran glycobiologyofpulmonaryarterialhypertension AT juliosebastiandomingo glycobiologyofpulmonaryarterialhypertension AT stefaniekrick glycobiologyofpulmonaryarterialhypertension AT jarrodwesleybarnes glycobiologyofpulmonaryarterialhypertension |